GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » Total Payout Ratio

Radiopharm Theranostics (Radiopharm Theranostics) Total Payout Ratio : 0.04 (As of Jun. 22, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Radiopharm Theranostics's current Total Payout Ratio is 0.04.

Radiopharm Theranostics Total Payout Ratio Historical Data

The historical data trend for Radiopharm Theranostics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Total Payout Ratio Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23
Total Payout Ratio
2.15 0.27

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Total Payout Ratio 2.67 1.45 0.74 - 0.09

Competitive Comparison of Radiopharm Theranostics's Total Payout Ratio

For the Biotechnology subindustry, Radiopharm Theranostics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radiopharm Theranostics's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Total Payout Ratio falls into.


Radiopharm Theranostics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Radiopharm Theranostics's Total Payout Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-0.574 + 6.76 + 0) / -23.229
=0.27

Radiopharm Theranostics's Total Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-0.011 + 1.415 + 0) / -16.572
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Radiopharm Theranostics (Radiopharm Theranostics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » Total Payout Ratio
Comparable Companies
ASX:NOX ASX:AGN ASX:EZZ ASX:PAA ASX:BIO ASX:CYP ASX:1AI ASX:ACW ASX:BTC ASX:IXC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
RAD:Australia
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Website
https://www.radiopharmtheranostics.com
Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (Radiopharm Theranostics) Headlines

From GuruFocus

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 07-10-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-20-2022

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire • 10-19-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-30-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-10-2022

RADIOPHARM ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND ASSUMES PD-L1 LICENSING AGREEMENT FROM NANOMAB

By PRNewswire PRNewswire • 08-04-2022